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Created in 2007, COMUSA is a multiprofessional committee 
comprising speech therapy, otology, otorhinolaryngology and 
pediatrics with the aim of debating and countersigning auditory 
health actions for neonatal, lactating, preschool and school 
children, adolescents, adults and elderly persons. COMUSA 
includes representatives of the Brazilian Audiology Academy 
(Academia Brasileira de Audiologia or ABA), the Brazilian 
Otorhinolaryngology and Cervicofacial Surgery Association 
(Associação Brasileira de Otorrinolaringologia e Cirurgia 
Cérvico Facial or ABORL), the Brazilian Phonoaudiology 
Society (Sociedade Brasileira de Fonoaudiologia or SBFa), the 
Brazilian Otology Society (Sociedade Brasileira de Otologia 
or SBO), and the Brazilian Pediatrics Society (Sociedade 
Brasileira de Pediatria or SBP).
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NEONATAL AUDITORY HEALTH
Universal neonatal auditory screening – UNAS
Because more hospital units are implementing 
universal neonatal auditory screening programs (UNAS), 
because state and city laws are being approved, because 
questions have been sent to entities by their associate 
members, and because of federal and state funded re-
search in neonatal auditory health, the abovementioned 
entities have decided to publish advice on UNAS as a 
guideline for professionals.   
INTRODUCTION AND BACKGROUND
Hearing develops in increasingly complex stages 
from intrauterine life onwards. For a child to acquire 
language and develop speech, he or she should be able 
to detect, locate, discriminate, memorize, recognize, 
and finally understand sounds.1,2,3,4 Any, and especially 
the initial of these steps, are extremely important for 
the whole process to take place;5,6, any interruption 
will result in significant loss of function during child 
development. Thus, measures should be undertaken 
promptly to minimize eventual difficulties doe to sen-
sory deprivation. Therefore, neonates with hearing loss 
should be identified within the first month of life, even 
if the clinical history reveals no indicators of risk for the 
probability of hearing loss.2,3,6,7,35 
The central nervous system is very plastic when 
stimulated early, before 12 months of age, which in-
creases the number of nerve connections and impro-
ves the results of auditory rehabilitation and language 
development in children with hearing loss.6,8,9,10  The 
first six months are decisive for future development; for 
this reason, speech therapists, otorhinolaryngologists 
and pediatricians have been concerned with promo-
ting awareness campaigns for the population and for 
healthcare professionals about the importance of early 
identification and diagnosis of hearing loss and prompt 
medical and phonoaudiological interventions.6,9,10,11,12,13,14
There are several causes of congenital hearing 
loss, which is acquired prenatally of within the first days 
following birth. Genetic recessive inherited auditory sys-
tem damage, which causes hearing loss not associated 
with any syndrome, is the most frequent cause of hea-
ring loss reported in developed countries; it generally 
is expressed early, before language develops. Other 
than heredity, the most common causes of congenital 
hearing loss are due to very low birth weight (less than 
1,500 g), hyperbilirubinemia, congenital infection such 
as rubella, toxoplasmosis, cytomegalovirus, syphilis, and 
neonatal use of ototoxic drugs. Children with head and 
neck malformations and and/or syndromes that include 
hearing loss may also be affected. It is common for 
such hearing loss risk factors to be associated among 
neonates, especially if they remain in neonatal ICUs 
for over five days.
It is not uncommon for the cause of hearing loss 
to remain unclear; hearing loss is idiopathic is about half 
of neonates. As such, selective neonatal auditory scree-
ning done only in children selected for hearing loss risk 
factors identifies about 50% of hearing loss patients.7,11,35 
Therefore, universal screening is the ideal method, and 
has been defended by all professionals acting in this 
area. UNAS is here understood as performing auditory 
tests in over 95% of neonates, preferably before being 
discharged from hospital.7
In developed countries, sensorineural hearing 
loss affects one in every 1,000 newborns; 40% are due to 
hereditary factors, 30% are due to a variety of acquired 
conditions, and 20% are of unknown etiology.15 There 
have been few population base studies of neonates in 
Brazil. A study in a private hospital in Sao Paulo from 
1996 to 1999 screening 4,631 neonates (90.6% of live 
births) found 10 children with permanent hearing loss 
(0.24%), a prevalence of 2.4/1000.16
A study of 200 children and adolescents by the 
Sao Paulo Federal University (UFSP) in 1998 revealed 
that diagnostic confirmation of hearing loss within the 
optimal neuronal plasticity phase – up to age 2 years 
– was made in only 13% of cases, even though parents 
had suspected hearing loss in 56% of cases in this age 
group. Time wasted – over two years – between sus-
pected and confirmed hearing loss occurred in 42% of 
cases, underlining the need for rethinking our health 
care model.17 Another study in 2005 at the same insti-
tution, involving 519 children and adolescents revealed 
that the main causes of hearing loss were: idiopathic 
(36.6%); genetic (13.6%), including 4.0% of consangui-
nity cases; congenital rubella (12.9%); perinatal causes 
(11.4%); meningitis (10.6%); and other causes (14.9%).18
Early functional and etiological diagnosis of he-
aring loss and prompt medical, phonoaudiological or 
surgical interventions minimize the effects of hearing 
loss in children.10 Developments in neonatal auditory 
screening and identification methods since the 1990s 
have led to greater efforts for diagnosing and initiating 
rehabilitation before six months of age.
Guidelines published in the US by the National 
Institutes of Health19 in 1993 and by the Joint Committee 
on infant Hearing in 199420 have led to a gradual and 
continuous implementation of UNAS throughout North-
American states. In 2006, 95.7% of newborns in 50 states 
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were assessed before being discharged from hospital.21
Also in the US, in 1999 the American Academy of 
Pediatrics recommended UNAS with quality metrics to 
be reached. Such indicators refer to carrying out neona-
tal auditory screening in at least 95% of live newborns 
and identifying hearing loss of at least 35dB in the best 
ear; they also suggest that there should be no more than 
4% false positives and that the rate of false negatives 
should be zero.22 The Joint Committee on Infant Hearing 
also underscored these guidelines in 2000.23
UNAS was recommended in Europe in 1998 in 
a consensus signed by several countries at a scientific 
event for this purpose. Below are the justifications for 
implementing UNAS:24
•	Permanent	hearing	loss	is	a	major	public	health	
issue; satisfactory results may be attained with treatment 
if interventions take place within the first months of life;
•	Effective	methods	are	available	in	clinical	prac-
tice to identify hearing loss; these methods include 
recording evoked otoacoustic emissions (EOAE) and 
the brainstem auditory evoked potential (BAEP);
•	Neonatal	auditory	screening	only	of	newborn	
babies at risk of hearing loss has been suggested as a 
lower cost strategy; it may, however, not identify about 
40-50% of children with permanent hearing loss;
•	UNAS	is	only	the	first	step	of	a	neonatal	auditory	
health program; diagnostic and rehabilitation measures 
should ensue.
In Brazil, the first multiprofessional guidelines 
on auditory health in children were published in 1995, 
the result of a workgroup that was organized in the X 
International Audiology Meeting (X Encontro Interna-
cional de Audiologia). The debate forum on “Hearing in 
Children” made recommendations for auditory health-
care in children, focusing on joint and multiprofessional 
actions in the public and private spheres to promote and 
protect auditory health. This document suggests early 
identification, diagnosis and rehabilitation according 
to the principles of integral healthcare for children.25
The Universal Neonatal Auditory Screening Su-
pport Group (GATANU) was created in Brazil in 1998; 
its aim was to disseminate and sensitize society to the 
need for an early diagnosis of deafness.26.
In 1999, the Brazilian Committee on Hearing Loss 
in Infancy (CBPAI), composed of speech therapists, 
otorhinolaryngologists and pediatricians, published 
guidelines on the need for identifying hearing loss in 
neonates and implementing the UNAS, preferably before 
the children were discharged from hospital. Auditory 
screening was recommended within three months of 
age for those born at home.27
In 2000, the Federal Board of Phonoaudiology 
published the Recommendation CFFa. nº 05/00, which 
suggested implementing auditory screening in neonates 
using objective methods published in medical literatu-
re, such as evoked otoacoustic emissions (EOAE) and 
the brainstem auditory evoked potential (BAEP). The 
recommendation also points out the required steps 
and the need for multiprofessional teams if a further 
diagnosis is required.28
Thus one can state that Brazil, for over the past 
10 years, has carried out actions to underline the im-
portance of identifying and treating hearing loss at an 
early age.
Several city and state laws making UNAS compul-
sory in maternity hospitals have been passed in Brazil. 
However, it is clear that few public maternity hospitals 
have a systematic UNAS program.29
By screening we mean a simple, quick and low 
cost process to identify children at a higher probability 
of having altered auditory function. Children that do 
not pass the screening tests should be referred for more 
complex diagnostic procedures.30
The following principles should be applied 
during screening procedures: the prevalence of the 
disorder being tested should justify universal screening; 
screening procedures should be sensitive and specific; 
diagnostic and treatment resources should be available; 
cost should be compatible with the desired effective-
ness; this actions should be accepted by healthcare 
professionals and the population.31
The most recent international publication con-
taining guidelines for UNAS was published in 2007 by 
the Joint Committee On Infant Hearing;32 it lists eight 
principles to provide an effective basis for early diag-
nostic and therapeutic systems:
1. All neonates should have priority access to 
UNAS with physiological measures within the first 
month of life;
2. All children with unsatisfactory test and retest 
UNAS results should have access to diagnostic measu-
res to confirm hearing loss within three months of life;
3. All children with confirmed permanent hearing 
loss should start treatment and intervention measures 
after diagnosis within six months of life;
4. Interventions should include family and care-
taker participation, respecting the rights of child and 
family, confidentiality, and the current ethical and legal 
requirements;
5. Children and their families should have prompt 
access to high quality and high complexity technology, 
such as sound amplification hearing aids and cochlear 
implants, as well as other support devices, whenever 
applicable;
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6. All normal hearing children should have their 
hearing, language development and communication 
ability monitored, even in the absence of hearing loss 
risk factors, by duly trained professionals:
7. Children with permanent hearing loss and their 
families should be followed-up by experienced interdis-
ciplinary teams in the care of children with hearing loss:
8. Computer database systems should be gene-
rated to monitor the results and effectiveness of identi-
fication, diagnosis and early intervention measures for 
hearing loss in neonates.
The Joint Committee on Infant Hearing32 recom-
mends using physiological procedures (EOAE and 
BAEP); for neonates with no hearing loss risk factors, 
any one of these methods is considered as appropriate. 
If BAEP testing is used in this population, it may be 
possible to identify neural auditory disorders, such as 
the auditory neuropathy spectrum, as well as cochlear 
hearing loss.33
The Joint Committee on Infant Hearing (2007)32 
comments the fact that some unit use EOAE recordin-
gs as initial screening, followed by BAEP testing if the 
former method fails, to decrease false positive rates and 
the need for future monitoring. Some caveats in that 
paper deserve attention: 1. Children that do not pass 
EOAE testing, and that present normal BAEP recordings, 
may eventually show mild losses (from 25 to 40 dB). 2. 
Care should be taken with adequate EOAE test results 
and failed BAEP recordings, as this finding suggests the 
auditory neuropathy spectrum.
For neonates with hearing loss risk factors, espe-
cially those admitted to neonatal ICUs, the Joint Com-
mittee on Infant Hearing32 recommends BAEP testing 
for screening purposes as the only appropriate method 
for this group, due to an increased occurrence of the 
auditory neuropathy spectrum. If auditory screening 
detects findings in children with hearing loss risk factors, 
prompt referral to an experienced pediatric medical 
team for retesting and diagnosis.32
Professionals who implement, coordinate or 
work, teach and research the UNAS are encouraged 
to read the Joint Committee on Infant Hearing (2007)32 
guidelines.
The US Preventive Services Task Force published 
similar guidelines in July 2008 for carrying our UNAS 
with EOAE or BAEP-A testing to identify 30-40 dB he-
aring losses; in this case, the process may include two 
steps (EOAE followed by BAEP-A) to improve sensitivity 
(0.92) and specificity (0.98). Auditory screening in neo-
nates should be done on the first day of life, preferably 
before the newborn is discharged from hospital. This 
particular North-American publication describes studies 
showing the strong contribution of UNAS for early diag-
nosis and intervention and the reliability of objective 
tests. Further publications on studies demonstrating the 
results for language development in children identified 
by applying the UNAS.35,42
Recent published studies have attempted answer 
language developmental issues in children with identi-
fied, diagnosed and treated conditions within the first 
months of life; it appears that such evidence is being 
demonstrated.41
Authors who have shown that this population 
group had a higher rate of retrocochlear hearing loss – 
not identifiable with EOAE recordings – have suggested 
using BAEP-A in the UNAS of higher risk children. The 
auditory neuropathy spectrum falls within this situation. 
Thus, low birth weight children, which generally pre-
sent other associated risk factors, and those admitted 
to neonatal ICUs, may require BAEP-A in the UNAS, 
because of increased synergy among risk indicators. 
Studies have shown that hearing needs to be monito-
red in these children because of the possibility of late 
onset hearing loss or the progression of hearing losses 
diagnosed at this initial point.36,40
The techniques and protocols are being described 
to reduce the number of false positives in UNAS. Use 
of EOAE and BAEP-A recording in different steps has 
shown a positive effect. Studies have shown that using 
EOAE as a first step, followed by BAEP-A as a second 
step, significantly decreases the number of neonates 
referred for diagnosis when there is initial failure of 
hearing.38,39
Although genetic congenital hearing losses are 
important, particularly those involving Conexin26, 
several unresolved technical and ethical issues lack 
evidence, so that neonatal screening for GJB2 is still 
not included. Genetic testing and counseling is recom-
mended after hearing loss is confirmed. So, studies are 
still needed before implementing neonatal screening 
for GJB2 mutations.37
The epidemiology of hearing loss in children in 
Brazil requires further study in order to put in effect 
preventive measures. There are few data on the deter-
mining factors and prevalence of hearing loss in neo-
nates. UNAS may help provide prompt interventions in 
children with hearing loss and foster appropriate public 
policies for this age group.
The National Policy for Auditory Healthcare is 
available in most of the country; there are 127 auditory 
health reference centers, of which 80 are high comple-
xity units able to care for neonates with specialized 
diagnostic needs and to select and provide sound am-
plification hearing aids and speech therapy. Maternity 
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hospitals with auditory health reference units for diag-
nosis and medical and phonoaudiological interventions 
may already implement neonatal auditory screening.34
COMUSA RECOMMENDATIONS
After analyzing the literature of data showing 
evidence on the identification, diagnosis and early 
intervention in neonates and lactating children with 
hearing loss, COMUSA recommends:
1. A neonatal auditory health program with all 
prevention, diagnosis and hearing loss rehabilitation 
measures should be implemented, as follows:
•	Promote	the	health	of	pregnant	women,	neo-
nates and lactating children;
•	Prevent	hearing	loss	by	applying	specific	me-
asures to be put in place following epidemiological 
prevalence and determinant factor studies on hearing 
loss in neonates;
•	Identify	hearing	loss	by	auditory	screening	with	
sensitive and specific methods; electrophysiological 
measures are recommended (brainstem auditory evoked 
potentials – BAEP) and/or electroacoustic methods 
(recording evoked otoacoustic emissions – EOAE – by 
transient or distortion product stimuli);
•	Make	available	referral	for	medical	and	audiolo-
gical diagnosis and laboratory tests, as needed; imaging 
and genetic evaluation may be required;
•	Make	 available	medical	 treatment	 and	 spee-
ch therapy, including the selection and indication of 
individual sound amplification hearing aids, cochlear 
implants, and family support, as needed;
•	Make	 available	 high	 quality	 technology,	 as-
suring adequate treatment for a good development 
of hearing, language acquisition, and consequently, 
educational and social development in children with 
hearing loss;
•	Medical	care	and	speech	therapy	should	respect	
the needs and choices of parents or caretakers of neo-
nates, offering different scientifically and technologically 
supported approaches and methods.
2. Implanting a universal neonatal auditory scree-
ning program (UNAS), for all neonates preferably before 
being discharged from hospital.
3. For home births, out of hospital environments, 
or in maternity hospitals that are still implementing 
universal auditory screening, tests should be one within 
the first month of life.
4. It is suggested that strategies for implementing 
UNAS in all maternity hospitals be written. Meanwhile, 
sites for carrying out auditory screening within the first 
months should be defined.
5. Implementation of a UNAS program may be 
gradual in order to better organize the necessary ac-
tions. The goal for implementing auditory screening 
universally, however, is three years.
6. It is suggested that a dissemination/information 
plan about this action for neonates be written during 
implementation of neonatal auditory screening, for both 
healthcare professionals and the general population, so 
that the importance of UNAS and its methods be widely 
known among the population.
7. It is suggested that every hospital with a neona-
tal auditory screening program should elect a maternity 
hospital coordinator for this action, such as a neona-
tologist, or otorhinolaryngologist or speech therapist 
with proven experience or specialization in audiology. 
In smaller municipalities or hospitals that are unable 
to elect such a coordinator, it is recommended that im-
plementation of a neonatal auditory screening program 
be carried by a healthcare professional supervised and 
supported by a coordinator from another hospital with 
experience in implementing UNAS. Scientific societies 
that undersign this document are ready to provide 
further information to their associate members about 
implementing a UNAS, helping supervise and legitima-
tize these programs.      
8. It is suggested that parents/caretakers receive 
explanations about the importance of UNAS, and that 
they be asked to sign a free informed consent form for 
the test, or a term of responsibility if they refuse the 
test. Furthermore, it is suggested that parents/caretakers 
sign upon receiving the results of tests and orientation 
before the neonate is discharged from hospital, for 
both normal and altered tests. All test results (test and 
retest) should be provided in printed form to parents/
caretakers.
9. For neonates with no indicated risk of hearing 
loss, the recommended method for UNAS is the tran-
sient or distortion product stimuli evoked otoacoustic 
emissions (EOAE) test. Its purpose is to identify coch-
lear hearing loss up to 35 dBHL. It is a low cost easily 
applied test, added to which this neonate population 
group has a low prevalence of auditory neuropathies.
10. Because of false negatives due to vernix in the 
outer ear in the first days of life, a second evaluation is 
recommended within 30 days of hospital discharge in 
all cases of absent (altered) EOAE, even if in one ear 
only. At this visit, both ears should be retested, even in 
test failure occurred in only one ear during the first test.
11. Cases where EOAE testing fails should under-
go automatic BAEP (BAEP-A) before being discharged 
from hospital and/or when being retested. This measure 
aims to reduce the number of unnecessary referrals 
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for diagnosis. Normal BAEP-A responses in both ears 
should be considered as satisfactory screening results. 
However, parents or caretakers should be informed that 
if hearing difficulties arise or are suspected, an auditory 
healthcare reference unit should be sought immediately.
12. If within 30 days screening tests fail, the 
patient should immediately be referred for a full 
otorhinolaryngological medical and phonoaudiological 
diagnosis. A diagnostic team consisting of otorhinolaryn-
gologists and speech therapists should have experience 
in evaluating neonates and lactating children.
13. For neonates with normal tests, orientation 
on the care of auditory health should be given, as well 
as a table for monitoring the development of hearing 
abilities and language, so that these may be observed 
within the family.
14. A copy of the test and relevant annotations 
should be annexed to the child’s records, including 
the data and signature of the healthcare professional 
in charge of the UNAS process, in the case of normal 
or altered tests, and with their referrals, if applicable.
15. For neonates with risk indicators of hearing 
loss, BAEP-A testing at 35 dBHL is recommended as the 
initial screening method. This method makes it possible 
to diagnose cochlear, retrocochlear, and sensorineural 
conditions, including the auditory neuropathy spectrum, 
which are more prevalent in the higher risk population. 
EOAE testing may be associated with BAEP-A, given the 
risk of more unsatisfactory results because of middle 
ear changes, but not because of permanent sensory 
hearing loss.
16. If BAEP-A recording are absent in the initial 
test of neonates at risk for hearing loss, it is recom-
mended that these patients be referred to diagnostic 
units immediately, without retesting, as described for 
other neonates.
17. All test results should be given to parents or 
caretakers, and annotated in the child’s health report 
and hospital records; parents or caretakers should sign 
an appropriate form or terms upon receiving the refer-
rals, results and orientation.
18. For neonates with risk indicators of hearing 
loss and satisfactory BAEP-A testing during screening, 
auditory function should be monitored by a trained 
professional until the third year of life.
19. The main hearing loss risk factors described 
in the specialized literature included any of the follo-
wing factors, and are therefore listed in these guideli-
nes:6,10,17,18,23,32
•	Parental	concern	with	child	development	with	
regards to hearing, speech or language;
•	History	of	permanent	deafness	cases	in	the	fa-
mily starting during infancy, and therefore considered a 
hereditary risk. Consanguinity cases should be included 
here; 
•	ICU	stay	for	over	five	days,	or	the	occurrence	
of any of the following conditions, regardless of the 
duration of ICU stay: extracorporeal ventilation, as-
sisted ventilation; exposure to ototoxic drugs such as 
aminoglicoside antibiotics and/or loop diuretics; hyper-
bilirubinemia; severe perinatal anoxia; neonatal Apgar 
score from 0 to 4 in the first minute or 0 to 6 in the fifth 
minute; birth weight below 1,500 grams; preterm birth, 
or low weight for the gestational age;
•	Congenital	 infections	(toxoplasmosis,	rubella,	
cytomegalovirus, herpes, syphilis, HIV infection);
•	Craniofacial	 anomalies	 involving	 the	 ear	 and	
temporal bone.
•	Genetic	syndromes	that	usually	express	hearing	
loss (Wardenburg, Alport, Pendred, among others);
•	Neurodegenerative	disorders	(Friedreich’s	ata-
xia, Charcot-Marie-Tooth syndrome);
•	Postnatal	bacterial	or	 viral	 infections	 such	as	




20. It is suggested that a computerized database 
on auditory neonatal auditory screening be made so that 
the coordinator may monitor the results monthly, and 
as a tracking tool for cases that may be lost to follow-
up, or that did not conclude all the necessary retest 
or diagnostic steps. Software is available, and other 
computer programs may be written by the information 
technology teams of states and municipalities.
21. Monthly, quarterly and annual reports should 
be made to help monitor the development of the neo-
natal auditory screening program, quality control, and 
tracking information. The same quality control metrics 
used in the auditory screening program of the Joint 
Committee on Infant Hearing (2007) are recommended:
•	Screening	indices	over	95%	of	live	births,	with	
attempts to reach 100% of live births; 
•	Screening	tests	should	be	carried	out	within	the	
first month of life;
•	A	 less	 than	 4%	 rate	 of	 neonates	 referred	 for	
diagnosis;
•	Quality	indicators	in	the	diagnosis	phase	are	the	
visit rates upon referral for diagnosis; 90% of referred 
neonates should be present and the diagnostic visit, and 
should have been diagnosed by three months of life;
•	It	is	suggested	that	95%	of	lactating	babies	with	
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confirmed permanent bilateral hearing loss should ini-
tiate use of sound amplification within one month of 
the diagnosis.
COMUSA DOES NOT RECOMMEND including 
genetic screening to identify hearing loss-related genetic 
abnormalities at this point in time, because of the need 
to investigate the cost, effectiveness and feasibility of 
genetic studies in maternity hospitals.
Implementing a UNAS program is only meanin-
gful if after its completion a correct diagnosis is made 
and auditory rehabilitation processes and language 
development are implemented in sequence.
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